Addex Moves R&D Operations to Geneva’s Campus Biotech

Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program

Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases

ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share

Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder

Addex Therapeutics Reports First Half 2015 Financial Results

Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy

Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field

Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics

Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease